Related Experiment Video
Updated: Aug 5, 2026
Synergetic Use of Neural Precursor Cells and Self-assembling Peptides in Experimental Cervical Spinal Cord Injury
Published on: February 23, 2015
Methylprednisolone in acute spinal cord injuries
P A O'Connor1, O McCormack, C Gavin
1National Spinal Injuries Unit, Department of Orthopaedic Surgery, Mater Misericordiae Hospital, Dublin, Ireland. paoconn@indigo.ie
Background:
Methylprednisolone is the only neuroprotective therapy advocated in acute non-penetrating spinal cord injury. Trials indicate improved neurological outcome following early administration of a high dose regime. The National Spinal Injuries Unit (NSIU) has promoted this regime by a simple laminated poster sent to all Irish A&E departments.
Aim:
To assess the use of methylprednisolone in patients with spinal cord injuries.
Methods:
A retrospective audit of patient data for all patients admitted with traumatic neurological impairment over a 12-month period.
Results:
One hundred ninety-six patients were admitted during the study period, 28 (14%) received intravenous methylprednisolone of which six had clear records documenting compliance. One patient received both dexamethasone and methylprednisolone in high doses and three had incorrect bolus dosages administered. Six patients received methylprednisolone infusion longer than the protocol, while five patients were given infusions shorter than recommended. Three patients were admitted to the unit that could have received the steroid regime at the point of transfer.
Conclusions:
There was poor documentation of prescription orders and timing of administration. Only six patients had clear documentation allowing confirmation of adherence to the protocol of the National Acute Spinal Cord Injury Study (NASCIS) III trial.
